Latest Posts
About This Stock
More About This Stock
Read
Read
ONTY And CLDX Announce Initiation Of Immunotherapy Clinical Trials; NPSP Initiates Study Of Teduglutide

Article By:
BioMedReports
Tuesday, November 11, 2014 3:05 AM EST
ONTY and CLDX announced they have initiated a combined clinical trial of ONT-10 and varlilumab. NPSP announced the company has initiated a global registration study of teduglutide in pediatric patients.
Bioniche: A Home Run Buying Opportunity In Biotech

Article By:
SecretCaps
Thursday, September 18, 2014 9:38 AM EST
There is a critical medical need for Bioniche's technology in a $1 billion market virtually free of real competition, which opens the door for massive revenue growth, while the sound financials limits downside risk. Overall, today's $0.20 share price appears to me as an excellent entry point...